SPRC - CONSENSUS CO - SciSparc Ltd

This chart of the market valuation for SciSparc Ltd (SPRC), where the figure stands at 0.00, is based on the company's success in developing innovative cannabinoid treatments for dementia and Alzheimer's disease. Patents and positive trial results are driving this growth. SciSparc Ltd (SPRC) minimizes risk by focusing on therapies for rare brain pathologies while outsourcing routine testing to external laboratories, thereby maintaining exclusive control over its intellectual property.

This indicator is calculated as a weighted average of expert target prices, determining the asset's fair value relative to the current market price to identify the investment gap. For SciSparc Ltd (SPRC), the aggregate target price history reflects the fundamental valuation of long-term patent revenues from CNS disorder therapies, allowing investors to weigh market skepticism against inertial demand for the drugs.